Lemilvo

Aripiprazole, the active ingredient in Lemilvo, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia, bipolar I disorder (manic or mixed episodes), serves as adjunctive therapy for major depressive disorder, and reduces irritability in autistic disorder among adults and adolescents. The medication is approved in the European Union and is prescribed by qualified healthcare professionals.

GNH USA supplies Lemilvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice, ensuring product integrity throughout the supply chain.

Aripiprazole is employed in the management of psychiatric disorders that involve dopamine and serotonin dysregulation.

- Schizophrenia: reduces positive and negative psychotic symptoms, improving thought organization, perception and overall functioning. - Bipolar I disorder (manic or mixed episodes): stabilizes mood, decreasing frequency and severity of manic episodes and preventing relapse. - Adjunctive treatment of major depressive disorder: enhances antidepressant efficacy when added to standard therapy, leading to greater remission rates. - Irritability associated with autistic disorder: lessens aggression, temper outbursts and improves emotional regulation in affected individuals.

Aripiprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Akathisia: inner restlessness and urge to move. - Insomnia: difficulty falling or staying asleep. - Nausea: mild gastrointestinal upset. - Headache: transient cranial pain. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and rigidity. - Tardive dyskinesia: persistent involuntary movements that may be irreversible. - Suicidal thoughts: emergence of suicidal ideation, especially in young adults.

Before initiating Lemilvo, clinicians should consider several safety measures.

- Monitor mental status: watch for worsening depression or emergence of suicidal thoughts. - Assess metabolic parameters: check weight, glucose, and lipid levels periodically. - Evaluate cardiovascular health: be cautious in patients with history of orthostatic hypotension. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep tablets below 25°C in the original pack, protect from moisture.

Aripiprazole can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase aripiprazole plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine, rifampin): may reduce aripiprazole exposure. - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis when combined.

Moderate Interactions (Monitor Closely): - Other antipsychotics or dopamine‑modulating agents: may increase risk of extrapyramidal symptoms. - CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation. - Antihypertensive drugs: aripiprazole may attenuate blood‑pressure‑lowering effects.